Skip to main content

Table 2 Univariate Analyses Results after missing value removal

From: Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer: application model for practice

Characteristics

HRD status

Negative vs positive

P value

Odds ratio

95%CI

Age(year)

0.97

0.93–1.01

0.176

BMI (kg/m2)

0.92

0.77–1.10

0.374

Family history

 No

Ref

  

 Yes

2.06

0.81–5.62

0.141

Marital status

 Unmarried

Ref

  

 Married

0.43

0.02–3.48

0.469

Menopause

 Premenopausal

   

 Menopause

1.23

0.44–3.68

0.694

Side classification

 Left

Ref

  

 Right

2.30

0.99–5.49

0.055

 Both

NC

NC

0.990

Pathological type

 Invasive cancer

Ref

  

 DCIS

NC

NC

0.98

Grade

 1

NC

NC

NC

 2

Ref

  

 3

3.07

1.23–8.12

0.019*

 Others

6.00

0.89–119.01

0.112

ER

 Negative

Ref

  

 Positive

0.32

0.13–0.77

0.011*

PR

 Negative

   

 Positive

0.32

0.13–0.78

0.014*

HER2

 Negative

Ref

  

 Low or positive

0.36

0.15–0.84

0.019*

Molecular subtype

 Luminal A

Ref

  

 Luminal B

2.00

0.22–43.12

0.568

 Triple-negative

6.50

0.77–136.50

0.116

 HER- 2 overexpression

3.00

0.07–170.77

0.547

T stage

 Tis- 1

Ref

  

 2–4

1.52

0.63–3.68

0.349

N stage

 0

Ref

  

 1–3

0.81

0.35–1.85

0.611

M stage

 0

Ref

  

 1

1.37

0.38–5.57

0.636

Stage

 0–II

Ref

  

 III–IV

1.20

0.50–2.95

0.686

CEA (ng/ml)

0.90

0.73–1.08

0.271

CA- 125 (U/ml)

1.00

1.00–1.01

0.430

CA153 (U/ml)

1.01

0.99–1.04

0.484

Ki- 67

32.18

4.22–306.29

0.001**

  1. Due to the presence of zero cells or very small numbers in the contingency table, some cell odds ratios are uncalculatable or infinite, which violates the statistical assumptions of OR calculation. HRD, homologous recombination deficiency; Ref, reference; NC, not calculable; BMI, body mass index; DCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; T, tumor size; Tis, tumor in situ; N, lymph node status; M, metastases; CEA, carcinoembryonic antigen; CA- 153, cancer antigen 15–3; CA- 125, antigen 12–5; P < 0.05 marked as *, P < 0.01 marked as **, P < 0.001 marked as ***